Avadel pharmaceuticals announces publication of data from pivotal phase 3 rest-on trial of ft218 in adults with narcolepsy in sleep

Dublin, ireland, aug. 16, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (eds) and cataplexy in adults with narcolepsy, announced today the publication of data from its pivotal phase 3 rest-on trial of ft218 in sleep, the journal of the sleep research society. the paper, titled “once-nightly sodium oxybate (ft218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy,” can be accessed at https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsab200/6343406?searchresult=1.
AVDL Ratings Summary
AVDL Quant Ranking